This refresh
Data-driven refresh June 27, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow), ranked across a 5223-ticker universe covering every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (2275 passed the market-cap / liquidity screen; financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90.2
Health Information Services · price $20.88 · 1Y $25.32 · 5Y $37.06 · 10Y $54.98
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A- · P/E 21.3x B+ · PEG 0.59 A-
Why now. Doximity's growth thesis rests on its ability to compound revenue at 13.1% year-over-year, driven by its personalized newsfeed and workflow tools like Ask and Scribe, with a $326m free cash flow, 21.3 P/E ratio, and 0.59 PEG ratio. The company's 30.4% profit margin and 20.6% ROE suggest a strong ability to maintain profitability. The crux of this thesis is the persistence of its 13.1% revenue growth, which is critical for justifying its current valuation.
Moat. Doximity's durable edge stems from its HIPAA-compliant AI assistant, Ask, and its clinical discussions platform, which create a network effect among medical professionals. The company's 20.6% ROE can be attributed to its pricing power, driven by its category leadership in providing a personalized newsfeed and workflow tools to its members. This advantage is difficult for competitors to replicate quickly, given the complexity and specificity of Doximity's platform.
Risk. The primary threat to Doximity's growth thesis is the potential for decelerating revenue growth, driven by increasing competition from other digital platforms for medical professionals. With a 1.29 beta, the stock's volatility is a concern, and a $3.8b market cap may not provide enough room for error. If Doximity's revenue growth were to slow significantly, it could confirm the bear case and break the bull thesis, particularly if the company's 13.1% revenue growth rate were to decline substantially.
Horizon. 1-3 yr $25.32 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $37.06 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $54.98 if current growth sustains into durable earnings power.
2. INTU — Intuit Inc. · score 89.9
Software - Application · price $267.72 · 1Y $488.17 · 5Y $714.73 · 10Y $1,060
FCF $7.8b B+ · Rev +15.6% B+ · D/E 0.33 B · P/E 16.3x A- · PEG 0.68 A-
Why now. The bull case for Intuit Inc. rests on its ability to compound growth through its QuickBooks services, which have driven a 15.6% revenue growth rate and a 21.9% profit margin, with a $7.8B free cash flow that demonstrates the company's ability to generate cash and invest in its business, all while maintaining a 0.68 PEG ratio that suggests the growth is still reasonably priced, and it all comes down to whether the company can continue to execute on its financial management and payments services for small and mid-market businesses.
Moat. Intuit's durable edge comes from its category leadership in financial management and payments services, particularly through its QuickBooks and Mailchimp offerings, which provide a 22.2% ROE driven by pricing power from its market position and the switching costs that make it difficult for customers to leave the platform, and this advantage is further reinforced by the company's ability to cross-sell and upsell its services to existing customers, creating a self-reinforcing cycle of growth and retention.
Risk. The bear case against Intuit centers on the potential for disruption from new competitors or substitutes in the financial management and payments space, which could erode the company's pricing power and margins, particularly if its 0.33 debt-to-equity ratio limits its ability to invest in new technologies or respond to changing market conditions, and a concrete signal that would confirm this risk is if the company's revenue growth rate were to slow significantly, say to below 10%, or if its profit margins were to contract, indicating that the competitive landscape is indeed shifting against it.
Horizon. 1-3 yr $488.17 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $714.73 at ~22% CAGR — compounding case rests on the competitive position widening. 10 yr $1,060 if current growth sustains into durable earnings power.
3. ADBE — Adobe Inc. · score 89.8
Software - Application · price $202.73 · 1Y $282.27 · 5Y $413.27 · 10Y $613.06
FCF $10.3b A- · Rev +10.5% B · D/E 0.61 C+ · P/E 11.6x A · PEG 0.54 A-
Why now. Adobe Inc. is a high-quality compounder with a strong growth trajectory, driven by its Digital Media segment which enables individuals and enterprises to create, publish, and promote content, with a 10.5% revenue growth rate, a $10.3B free cash flow, and a 11.6 P/E ratio, all of which suggest the company's growth persists due to its ability to execute and expand its customer base, resting on its 28.7% profit margin.
Moat. The company's durable edge is protected by its Digital Experience segment, which provides an integrated platform for brands and businesses to create, manage, and optimize customer experiences, with a 62.8% ROE driven by pricing power from category leadership in digital media and customer experience management, making it difficult for competitors to quickly replicate its offerings and scale.
Risk. The strongest argument against Adobe Inc. is the potential for a decline in its Digital Media segment due to increased competition from new entrants, with a 1.4 beta indicating higher volatility, and a $190–$460 analyst target range suggesting a wide range of possible outcomes, with the bear case confirmed if the company's revenue growth rate decelerates significantly, such as below 5%.
Horizon. 1-3 yr $282.27 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $413.27 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $613.06 if current growth sustains into durable earnings power.
4. LRN — Stride, Inc. · score 89.6
Education & Training Services · price $87.12 · 1Y $100.19 · 5Y $146.69 · 10Y $217.60
FCF $414m C · Rev +17.9% B+ · D/E 0.33 A- · P/E 13.6x A- · PEG 0.48 A
Why now. The bull case for LRN rests on its ability to compound growth through its integrated package of systems, services, and products for virtual or blended public schools, with a 17.9% revenue growth rate, a 13.6 P/E ratio, and a 0.48 PEG ratio, all of which suggest a high-quality growth franchise. The crux of this thesis is that LRN can sustain its 12.2% profit margin and 18.8% ROE, driven by its technology-based products and services that enable clients to support individualized learning for students.
Moat. LRN's durable edge comes from its proprietary online curriculum, software systems, and educational services, which create a cost advantage and switching cost for its clients. The company's 18.8% ROE is driven by its pricing power from category leadership in the virtual and blended public school market, making it difficult for competitors to quickly replicate its business model.
Risk. The bear case for LRN is that its 0.33 debt-to-equity ratio and 0.08 beta may not fully capture the risks associated with its concentrated exposure to the virtual and blended public school market. If the company's revenue growth decelerates or its profit margin contracts, the stock's 13.6 P/E ratio may be at risk of compression, confirming the bear case.
Horizon. 1-3 yr $100.19 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $146.69 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $217.60 if current growth sustains into durable earnings power.
5. PCTY — Paylocity Holding Corporation · score 89.3
Software - Application · price $106.35 · 1Y $154.16 · 5Y $225.70 · 10Y $334.81
FCF $487m C · Rev +14.8% B+ · D/E 0.11 B+ · P/E 22.7x B+ · PEG 0.82 B+
Why now. The bull case for PCTY rests on its ability to compound growth through its cloud-based human capital management and payroll software solutions, with a 14.8% revenue growth rate and $487m in free cash flow, all while maintaining a 16.1% profit margin and 21.9% ROE, which suggests the company's pricing power and operational efficiency will persist, hinging on its ability to continue delivering high-quality solutions to its customers.
Moat. PCTY's durable edge stems from its comprehensive suite of HR and payroll solutions, including time and attendance, scheduling, and talent management, which creates a sticky customer base due to the high switching costs and integration requirements, while its 0.11 debt-to-equity ratio provides the financial flexibility to invest in further innovation and customer acquisition, with its 21.9% ROE driven by pricing power from category leadership in cloud-based HCM and payroll software.
Risk. The bear case against PCTY centers around its valuation, with a 22.7 P/E ratio and $5.7b market cap, which may be elevated given the 14.8% revenue growth rate, and the risk that competition from other HCM and payroll software providers could erode its pricing power and margin, with a 0.51 beta indicating some sensitivity to market volatility, and the bear case would be confirmed if PCTY's revenue growth rate were to decelerate significantly or its profit margin were to contract.
Horizon. 1-3 yr $154.16 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $225.70 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $334.81 if current growth sustains into durable earnings power.
6. INCY — Incyte Corporation · score 89.1
Biotechnology · price $113.75 · 1Y $110.26 · 5Y $161.43 · 10Y $239.47
FCF $1.4b C+ · Rev +21.2% A- · D/E 0.01 A · P/E 16.1x A- · PEG 0.36 A
Why now. The bull case for Incyte Corporation rests on its ability to compound growth through its robust product lineup, particularly JAKAFI, which treats myelofibrosis and polycythemia vera, driving a 21.2% revenue growth rate. With a peg ratio of 0.36, the stock is attractively valued for its growth profile, and its 26.7% profit margin suggests a high-quality earnings stream. The crux of this thesis is that Incyte can sustain its growth trajectory, fueled by its commercialized products and promising pipeline, which would justify its current valuation and drive further upside.
Moat. Incyte's durable edge stems from its proprietary products like JAKAFI and ICLUSIG, which have demonstrated efficacy in treating rare and serious diseases, thereby commanding premium pricing due to their high value to patients and the healthcare system. The 25.5% ROE is a testament to the pricing power Incyte enjoys, driven by its category leadership in specific therapeutic areas. This advantage is difficult for competitors to replicate quickly, given the significant investment required to develop and commercialize similar therapies.
Risk. The bear case against Incyte centers on the potential for increased competition in its therapeutic areas, particularly from emerging therapies that could challenge the market share of JAKAFI and other Incyte products. With a debt-to-equity ratio of 0.01, Incyte has a clean balance sheet, but a significant decline in its product sales due to competition could impact its ability to sustain growth and maintain its valuation, potentially confirming the bear case if Incyte's revenue growth begins to decelerate sharply.
Horizon. 1-3 yr $110.26 (analyst consensus (n=23)) — fundamentals + valuation re-rating. 5 yr $161.43 at ~7% CAGR — compounding case rests on the competitive position widening. 10 yr $239.47 if current growth sustains into durable earnings power.
7. NBIX — Neurocrine Biosciences, Inc. · score 87.3
Drug Manufacturers - Specialty & Generic · price $168.52 · 1Y $194.38 · 5Y $284.59 · 10Y $422.17
FCF $831m C+ · Rev +21.4% A- · D/E 0.14 B+ · P/E 25.9x B · PEG 0.47 A
Why now. The bull case for NBIX rests on its ability to compound growth through its portfolio of neurological, psychiatric, endocrine, and immunological disorder treatments, led by products like INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, with a 21.4% revenue growth rate, a 25.9 P/E ratio indicating reasonable valuation, and a 0.47 PEG ratio suggesting growth is undervalued. This growth is further supported by a $831m free cash flow, indicating strong financial health. The crux of this thesis is the persistence of this high growth rate, driven by the continued demand for effective treatments in these disorder categories.
Moat. NBIX's durable edge stems from its portfolio of unique treatments, such as Orilissa tablets for endometriosis and Oriahnn capsules for uterine fibroids, which create switching costs for patients and physicians due to their efficacy and the specific conditions they address. The company's 19.6% ROE suggests pricing power, likely due to its category leadership in certain neurological and endocrine disorder treatments, making it difficult for competitors to quickly replicate its success.
Risk. The bear case against NBIX is centered on its dependence on a few key products and the potential for increased competition in the neurological and endocrine disorder treatment markets, which could lead to a contraction in its 21.6% profit margin. With a 0.4 beta, the stock's volatility is relatively low, but the $144–$250.65 analyst target range indicates significant uncertainty. A confirmation of the bear case would be a decline in revenue growth rate coupled with an inability to expand its product portfolio effectively.
Horizon. 1-3 yr $194.38 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $284.59 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $422.17 if current growth sustains into durable earnings power.
8. ADMA — ADMA Biologics, Inc. · score 87.2
Biotechnology · price $8.75 · 1Y $17.60 · 5Y $25.77 · 10Y $38.23
FCF $108m C · Rev +19.6% B+ · D/E 1.11 C · P/E 12.9x A- · PEG 0.66 A-
Why now. The bull case for ADMA Biologics, Inc. rests on its ability to compound growth through its specialty plasma-derived biologics, particularly with products like BIVIGAM and ASCENIV, which treat primary humoral immunodeficiency, supported by a 19.6% revenue growth rate, a 12.9 P/E ratio, and a 0.66 PEG ratio, all of which suggest that the company's growth is both substantial and reasonably valued, with the crux being its ability to sustain this growth rate.
Moat. ADMA's durable edge is its portfolio of FDA-approved products like Nabi-HB for Hepatitis B treatment and its intravenous immune globulin (IVIG) products, which provide a high barrier to entry due to stringent regulatory requirements and the company's established manufacturing capabilities, further reinforced by its 42.4% ROE, indicating pricing power and efficiency in its operations, particularly in the Plasma Collection Centers segment.
Risk. The bear case against ADMA is centered around its debt-to-equity ratio of 1.11, which, combined with a beta of 0.73, suggests that the company's financial leverage and market volatility could pose significant risks, especially if the growth in revenue begins to decelerate, with a concrete signal of trouble being a decline in profit margin below 30%, which would undermine the bull thesis of sustained growth.
Horizon. 1-3 yr $17.60 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $25.77 at ~24% CAGR — compounding case rests on the competitive position widening. 10 yr $38.23 if current growth sustains into durable earnings power.
9. NVDA — NVIDIA Corporation · score 86.6
Semiconductors · price $192.53 · 1Y $298.93 · 5Y $437.67 · 10Y $649.25
FCF $119.1b A · Rev +65.5% A · D/E 0.07 A- · P/E 29.5x B · PEG 0.61 A-
Why now. The bull case for NVDA rests on its dominant position in the data center scale AI infrastructure market, driven by its Compute & Networking segment, which has delivered 65.5% revenue growth FY YoY, with a $119.1b free cash flow TTM, and a 29.5 P/E ratio that is justified by its 63% profit margin and 81.7% ROE, all of which support the thesis that NVDA's growth will persist, and the stock will reach the analyst consensus 1-yr target of $298.93, which is the crux of the bull case.
Moat. NVDA's durable edge is its category leadership in the data center accelerated computing and networking platforms, which provides pricing power, as evidenced by its 81.7% ROE, driven by its high-margin Graphics segment, including GeForce GPUs for gaming and PCs, and Quadro/NVIDIA RTX GPUs for enterprise workstation graphics, making it difficult for competitors to replicate its business model and margins.
Risk. The bear case against NVDA is that its 2.2 beta and $4.7T market cap make it vulnerable to market downturns, and its 0.61 PEG ratio may indicate that the stock is overvalued, especially if revenue growth decelerates, which would confirm the bear case and break the bull thesis, particularly if the company's debt-to-equity ratio of 0.07 increases, indicating a potential increase in financial leverage.
Horizon. 1-3 yr $298.93 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $437.67 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $649.25 if current growth sustains into durable earnings power.
10. EXLS — ExlService Holdings, Inc. · score 86.4
Information Technology Services · price $26.00 · 1Y $41.75 · 5Y $61.13 · 10Y $90.68
FCF $297m C · Rev +13.6% B+ · D/E 0.67 C+ · P/E 16.6x A- · PEG 0.84 B+
Why now. The bull case for EXLS rests on its ability to compound growth through its data and artificial intelligence services, particularly in the Insurance and Healthcare segments, where it provides claims management, premium and benefit administration, and analytics-driven services, with a 13.6% revenue growth rate, a 16.6 P/E ratio, and a 0.84 PEG ratio, all of which suggest a strong and sustainable growth trajectory, which hinges on the company's ability to maintain its 11.7% profit margin.
Moat. EXLS's durable edge stems from its expertise in digital operations and solutions, and analytics-driven services, particularly in the Insurance and Healthcare segments, where it has built strong relationships with clients, and its 32.3% ROE suggests that it has significant pricing power, which is likely due to its category leadership in these segments, and its ability to provide high-quality services that are difficult for competitors to replicate.
Risk. The bear case for EXLS is that its growth may slow down due to increasing competition in the data and artificial intelligence services market, particularly from larger players, and its 0.67 debt-to-equity ratio and 0.82 beta suggest that it may be vulnerable to economic downturns, and if the company's revenue growth rate were to slow down significantly, it could confirm the bear case and break the bull thesis.
Horizon. 1-3 yr $41.75 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $61.13 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $90.68 if current growth sustains into durable earnings power.
11. CARG — CarGurus, Inc. · score 84.9
Auto & Truck Dealerships · price $33.03 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +13.7% B+ · D/E 0.79 B · P/E 17.4x B+ · PEG 0.95 B+
Why now. CarGurus, Inc. is a compelling growth investment due to its ability to compound revenue at 13.7% year-over-year, driven by its online automotive marketplace that connects a large audience of car shoppers with an extensive network of dealers, with a profit margin of 15.9% and a PEG ratio of 0.95, indicating the stock is reasonably valued given its growth prospects, all while generating $293m in free cash flow.
Moat. The company's durable edge stems from its integrated suite of products, including Digital Deal and Dealership Mode, which provide a seamless car-buying experience, resulting in a high ROE of 62.9% due to its pricing power from category leadership in the online automotive marketplace, making it difficult for competitors to replicate its business model quickly.
Risk. The primary risk to the bull case is the company's dependence on dealer subscription fees and advertising revenue, which could be impacted by a decline in the automotive market, with a debt-to-equity ratio of 0.79 and a beta of 1.21, indicating a higher level of volatility, and if the company's revenue growth decelerates, it could lead to a re-rating of the stock, confirming the bear case.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
12. IT — Gartner, Inc. · score 84.4
Information Technology Services · price $134.96 · 1Y $165.00 · 5Y $241.58 · 10Y $358.36
FCF $1.3b C+ · Rev +3.7% C+ · D/E n/a · P/E 13.3x A- · PEG 0.53 A-
Why now. The bull case for Gartner, Inc. rests on its ability to compound growth through its Insights segment, which delivers high-margin, recurring revenue and has a 13.3 P/E ratio, a 0.53 PEG ratio, and 11.4% profit margin, indicating a strong and sustainable business model. This, combined with a $1.3B free cash flow and 3.7% revenue growth, positions the company for long-term success, all of which hinges on the continued demand for its insights and research services.
Moat. Gartner's durable edge comes from its extensive network of business and technology experts, which provides a unique value proposition to its clients, making it difficult for competitors to replicate. This network effect, combined with its high-margin Insights segment, allows Gartner to maintain its pricing power and profitability, as evidenced by its 11.4% profit margin.
Risk. The bear case against Gartner, Inc. is centered around its dependence on the Conferences segment, which may be vulnerable to economic downturns and changes in corporate travel policies, potentially impacting its 3.7% revenue growth. Additionally, the company's 0.93 beta indicates a relatively high sensitivity to market fluctuations, which could confirm the bear case if the market experiences a significant downturn.
Horizon. 1-3 yr $165.00 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $241.58 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $358.36 if current growth sustains into durable earnings power.
13. EPAM — EPAM Systems, Inc. · score 83.9
Information Technology Services · price $80.68 · 1Y $144.06 · 5Y $210.91 · 10Y $312.87
FCF $544m C+ · Rev +15.4% B+ · D/E 0.08 B+ · P/E 11.6x A · PEG 0.40 A
Why now. The bull case for EPAM rests on its ability to compound growth through its digital platform engineering and software development services, with a 15.4% revenue growth rate and a 11.6 P/E ratio, which is supported by its 7% profit margin. This growth is driven by its cloud services, data, analytics, and artificial intelligence offerings, which position the company for long-term success. The crux of this thesis is that EPAM can maintain its growth trajectory, driven by its 0.4 PEG ratio, indicating a reasonable valuation for its growth prospects.
Moat. EPAM's durable edge is its ability to provide integrated engineering practices and smart automation services, which creates a switching cost for its clients. Additionally, its 11.3% ROE is driven by its pricing power in the digital platform engineering and software development market, where it has established a strong reputation. This advantage is difficult for competitors to replicate quickly, as it requires significant investment in talent, technology, and process development.
Risk. The bear case for EPAM is that its high 1.4 beta and 0.08 debt-to-equity ratio may indicate a higher risk profile, which could be exacerbated by a downturn in the technology sector. Furthermore, the company's $73.06 52-week low may suggest that the stock is volatile and sensitive to market fluctuations. If EPAM's revenue growth rate were to slow down significantly, it could confirm the bear case and break the bull thesis.
Horizon. 1-3 yr $144.06 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $210.91 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $312.87 if current growth sustains into durable earnings power.
14. DXCM — DexCom, Inc. · score 83.3
Medical Devices · price $70.14 · 1Y $85.24 · 5Y $124.80 · 10Y $185.13
FCF $1.4b C+ · Rev +15.6% B+ · D/E 0.47 B · P/E 30.1x C+ · PEG 1.30 B
Why now. The bull case for DXCM rests on its ability to compound growth through its continuous glucose monitoring (CGM) systems, specifically the Dexcom G7 and G7 15 Day, with a 15.6% revenue growth rate and a 19.3% profit margin, driven by a $1.4B free cash flow, all of which position the company for sustained expansion in the diabetes management market.
Moat. DXCM's durable edge stems from its integrated CGM systems like Dexcom G7, which offers a unique value proposition to endocrinologists, physicians, and diabetics, supported by a 31.5% return on equity, driven by pricing power from category leadership in CGM systems, making it difficult for competitors to quickly replicate its offerings.
Risk. The bear case against DXCM centers on its elevated 30.1 P/E ratio and 1.44 beta, indicating a potentially overvalued stock with high volatility, and the risk that the 0.47 debt-to-equity ratio could become a burden if growth slows, which would confirm the bear case and undermine the bull thesis.
Horizon. 1-3 yr $85.24 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $124.80 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $185.13 if current growth sustains into durable earnings power.
15. VEEV — Veeva Systems Inc. · score 82.9
Health Information Services · price $171.36 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.3% B+ · D/E 0.01 A- · P/E 30.4x C+ · PEG 0.73 A-
Why now. Veeva Systems Inc. is a compelling growth investment due to its strong position in the life sciences industry, driven by products like Veeva Vault CRM Suite and Veeva Medical, with a 16.3% revenue growth rate, a 28.4% profit margin, and a 12.9% ROE, all of which suggest a durable growth trajectory. The company's ability to maintain high margins while growing revenue rests on its ability to compound its customer base and expand its product offerings. The crux of this thesis is the persistence of its 30.4 P/E ratio, which, given its 0.73 PEG ratio, indicates the market expects continued strong growth.
Moat. Veeva's durable edge stems from its comprehensive suite of cloud-based software solutions, including Veeva Commercial Cloud and Veeva Data Cloud, which provide significant switching costs for its life sciences customers. The company's high ROE is attributed to its pricing power, derived from its category leadership in providing critical software infrastructure to the pharmaceutical and biotechnology industries. This advantage is difficult for competitors to replicate quickly due to the high barriers to entry in developing such specialized and integrated software solutions.
Risk. The strongest argument against Veeva is the potential for decelerating growth due to increasing competition in the life sciences software market, particularly from larger, more diversified technology companies. The bears point to the company's 0.95 beta as a sign of volatility and the $165–$350 analyst target range as indicative of significant uncertainty. A concrete signal that would confirm the bear case is a significant drop in revenue growth rate, below 10%, which would challenge the bull thesis of persistent high growth.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
16. META — Meta Platforms, Inc. · score 82.5
Internet Content & Information · price $550.25 · 1Y $827.32 · 5Y $1,211 · 10Y $1,797
FCF $48.3b A · Rev +22.2% A- · D/E 0.36 B+ · P/E 20.0x B · PEG 0.81 B+
Why now. The bull case for META rests on its ability to compound growth through its Family of Apps (FoA) segment, which includes Facebook, Instagram, and Messenger, with a 22.2% revenue growth rate and a 20 P/E ratio that's reasonable for a growth name, especially with a 0.81 PEG ratio indicating undervaluation. This growth persistence is crucial as it underpins the long-term thesis.
Moat. META's durable edge comes from its network effects across the FoA segment, where users attract more users, creating a self-reinforcing cycle that competitors can't quickly replicate. The 29% ROE is a testament to the pricing power from category leadership in social media and online messaging, allowing the company to maintain high profit margins.
Risk. The bear case against META centers on its debt-to-equity ratio of 0.36 and a beta of 1.23, indicating a potential for volatility. If the company fails to manage its debt and navigate market fluctuations, it could confirm the bear thesis, especially if the $48.3B in free cash flow (FCF) starts to decline, signaling a downturn in its financial health.
Horizon. 1-3 yr $827.32 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $1,211 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $1,797 if current growth sustains into durable earnings power.
17. CVSA — Covista Inc. · score 82.3
Education & Training Services · price $127.53 · 1Y $156.25 · 5Y $228.77 · 10Y $339.36
FCF $336m C · Rev +12.9% B+ · D/E 0.54 B+ · P/E 18.6x B · PEG 0.88 B+
Why now. Covista Inc. is a compelling growth compounder due to its strong position in the healthcare education market, particularly through its Chamberlain and Walden segments, with a 12.9% revenue growth rate and $336m in free cash flow, all while maintaining a 18.6 P/E ratio, suggesting a durable growth trajectory that can persist.
Moat. The company's moat is rooted in its ability to offer a wide range of degree and non-degree programs in healthcare education, creating switching costs for its students and a network effect that reinforces its market position, with a 17.2% ROE that reflects its pricing power and category leadership in the healthcare education space.
Risk. The primary risk to the bull case is the company's debt-to-equity ratio of 0.54, which, while manageable, could become a concern if interest rates rise or growth slows, potentially contracting margins and making it harder for the company to service its debt, a scenario that would be confirmed if the company's profit margin begins to contract significantly from its current 12.3% level.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $228.77 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $339.36 if current growth sustains into durable earnings power.
18. RMD — ResMed Inc. · score 82.3
Medical Instruments & Supplies · price $200.29 · 1Y $260.60 · 5Y $381.54 · 10Y $566.00
FCF $1.8b C+ · Rev +9.8% B · D/E 0.13 B+ · P/E 19.3x B+ · PEG 1.16 B+
Why now. ResMed Inc. is a compelling growth investment due to its strong position in the sleep and respiratory care market, driven by products like ApneaLink Air and NightOwl, with a 19.3 P/E ratio, 1.16 PEG ratio, and 9.8% revenue growth, all of which suggest the company's growth trajectory will persist, resting on its ability to maintain a 27.4% profit margin
Moat. ResMed's durable competitive advantage stems from its category leadership in sleep and respiratory care, with a 23.4% ROE driven by pricing power from its proprietary products like ApneaLink Air, creating a high barrier to entry for competitors and protecting its market share, as evidenced by its low 0.13 debt-to-equity ratio
Risk. The primary risk to ResMed's growth thesis is the potential for increased competition from lower-cost diagnostic devices, which could erode its 27.4% profit margin and slow its 9.8% revenue growth, with a 1.16 PEG ratio and 19.3 P/E ratio leaving little room for error, and a confirmed bear case would be signaled by a decline in its $1.8B free cash flow
Horizon. 1-3 yr $260.60 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $381.54 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $566.00 if current growth sustains into durable earnings power.
19. MELI — MercadoLibre, Inc. · score 82.1
Internet Retail · price $1675.10 · 1Y $2,217 · 5Y $3,246 · 10Y $4,815
FCF $11.8b A- · Rev +34.3% A · D/E 1.70 C+ · P/E 44.2x C · PEG 1.02 B+
Why now. MercadoLibre's 34.3% revenue growth rate, driven by its Mercado Libre Marketplace and Mercado Pago financial technology solution, positions the company for sustained compounding, with a 44.2 P/E ratio and 1.02 PEG ratio indicating the market is pricing in this growth, all while the company maintains a 26.4% ROE, resting on its ability to maintain this growth trajectory.
Moat. MercadoLibre's durable edge stems from its Mercado Pago platform, which offers a comprehensive set of financial technology services, creating a network effect that increases switching costs for its users, while its 26.4% ROE is driven by pricing power from category leadership in Latin American e-commerce, making it difficult for competitors to replicate its business model.
Risk. The primary threat to MercadoLibre is its 1.7 debt-to-equity ratio and 1.35 beta, indicating a higher level of financial leverage and market volatility, which could be exacerbated by a decline in the Latin American e-commerce market or increased competition from new entrants, with a concrete signal of trouble being a decline in its 8.6% profit margin.
Horizon. 1-3 yr $2,217 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,246 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $4,815 if current growth sustains into durable earnings power.
20. PRDO — Perdoceo Education Corporation · score 81.8
Education & Training Services · price $33.33 · 1Y $38.33 · 5Y $56.12 · 10Y $83.25
FCF $225m C · Rev +24.2% A- · D/E 0.12 A- · P/E 12.7x A- · PEG 0.71 A-
Why now. The bull case for Perdoceo Education Corporation rests on its ability to compound growth through its career-oriented disciplines, particularly in the CTU segment, with 24.2% revenue growth and a 12.7 P/E ratio, which is supported by a 0.71 PEG ratio, indicating the stock is undervalued given its growth prospects. This growth is driven by the increasing demand for online and blended learning programs, and Perdoceo's strong position in this market. The crux of this thesis is that Perdoceo can maintain its revenue growth trajectory, driven by its CTU and AIUS segments, and expand its profit margins, leading to a higher stock price.
Moat. Perdoceo's durable edge lies in its established position in the postsecondary education market, with a strong brand and a wide range of academic programs, including those in business and management, nursing, and healthcare management. The company's 17% ROE is a result of its pricing power, driven by its category leadership in career-oriented disciplines, and its ability to maintain a low 0.12 debt-to-equity ratio, which provides financial flexibility and reduces the risk of default. This moat is protected by the high switching costs for students and the company's strong distribution network.
Risk. The bear case for Perdoceo Education Corporation is that the company's growth may slow down due to increasing competition in the online education market, particularly from newer players with more innovative platforms. The company's 0.69 beta indicates that it is less volatile than the market, but a slowdown in growth could lead to a re-rating of the stock, particularly if the 12.7 P/E ratio is not supported by future earnings growth. A concrete signal that would confirm the bear case is a decline in revenue growth, particularly in the CTU segment, which would indicate that the company is losing market share to competitors.
Horizon. 1-3 yr $38.33 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $56.12 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $83.25 if current growth sustains into durable earnings power.
21. EPAC — Enerpac Tool Group Corp. · score 79.7
Specialty Industrial Machinery · price $36.78 · 1Y $42.30 · 5Y $61.93 · 10Y $91.86
FCF $111m C · Rev +4.6% C+ · D/E 0.46 B+ · P/E 23.1x B+ · PEG 0.34 A
Why now. The bull case for EPAC rests on its ability to compound growth through its highly engineered heavy lifting technology solutions and branded tools, with a 23.1 P/E ratio indicating a growth premium, 4.6% revenue growth, and a 0.34 PEG ratio suggesting undervaluation. This growth is driven by its presence in the infrastructure, industrial maintenance, and oil and gas markets. The crux of this thesis is that EPAC can maintain its 13.7% profit margin and 21% ROE, driven by its pricing power in the heavy lifting solutions segment.
Moat. EPAC's durable edge comes from its highly engineered heavy lifting technology solutions, which provide a cost advantage and switching costs for its customers. The 21% ROE is a result of pricing power from category leadership in heavy lifting solutions, which is difficult for competitors to replicate quickly. Additionally, EPAC's global distribution network and brand recognition in the industrial tools market provide a barrier to entry for new competitors.
Risk. The bear case against EPAC is that its 0.46 debt-to-equity ratio and 0.87 beta indicate a higher risk profile, and the 23.1 P/E ratio may be elevated given the 4.6% revenue growth. A decline in demand from the oil and gas or infrastructure markets could lead to a contraction in EPAC's profit margin, confirming the bear case and breaking the bull thesis.
Horizon. 1-3 yr $42.30 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $61.93 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $91.86 if current growth sustains into durable earnings power.
22. FIVE — Five Below, Inc. · score 79.5
Specialty Retail · price $188.37 · 1Y $261.57 · 5Y $382.97 · 10Y $568.11
FCF $505m C+ · Rev +22.9% A- · D/E 0.86 B · P/E 23.8x B · PEG 0.98 B+
Why now. The bull case for Five Below, Inc. rests on its ability to compound growth through its diverse product offerings, including classic and novelty candy bars, personal care essentials, and party goods, with a trailing twelve months price-to-earnings ratio of 23.8, a price-to-sales ratio of 2.1, and a revenue growth rate of 22.9%. This growth is driven by the company's strong position in the specialty value retail market, where it can leverage its pricing power and 19% return on equity to expand its customer base and increase sales. The crux of this thesis is that Five Below can maintain its revenue growth rate while expanding its profit margins, driven by its 8.7% profit margin and $505m in free cash flow.
Moat. Five Below's durable competitive advantage stems from its ability to offer a wide range of products at a low price point, creating a strong value proposition for its customers. The company's 19% return on equity is driven by its pricing power, which is a result of its category leadership in the specialty value retail market. Additionally, the company's diverse product offerings, including its own branded cosmetics and skincare products, create a switching cost for customers, making it difficult for competitors to replicate its business model.
Risk. The bear case for Five Below, Inc. is that the company's debt-to-equity ratio of 0.86 and beta of 0.97 indicate a higher level of risk, which could be exacerbated by a decline in consumer spending or an increase in competition from online retailers. If the company's revenue growth rate were to slow significantly, its valuation multiples, including its 23.8 price-to-earnings ratio, could contract, leading to a decline in the stock price. A concrete signal that would confirm the bear case is a decline in same-store sales or a significant increase in inventory levels.
Horizon. 1-3 yr $261.57 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $382.97 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $568.11 if current growth sustains into durable earnings power.
23. PODD — Insulet Corporation · score 79
Medical Devices · price $158.25 · 1Y $240.25 · 5Y $351.75 · 10Y $521.80
FCF $416m C · Rev +30.7% A · D/E 0.78 C+ · P/E 36.9x C+ · PEG 1.31 B
Why now. The bull case for PODD rests on the Omnipod platform's ability to drive 30.7% revenue growth, with a $416m free cash flow and a 36.9 P/E ratio that's justified by the company's growth prospects, all of which are underpinned by the Omnipod 5 automated insulin delivery system and its integration with third-party continuous glucose monitors, which will persist as the company continues to compound at a high rate, with the crux being the ability to maintain this growth rate.
Moat. Insulet's durable edge comes from its proprietary AID algorithm embedded in the Omnipod 5, which provides a cost advantage and high switching costs for customers, as well as its 23.2% ROE driven by pricing power from category leadership in the insulin delivery systems market, making it difficult for competitors to quickly replicate the company's offerings and margins.
Risk. The bear case against PODD is centered around the company's 1.31 PEG ratio and 1.13 beta, which suggest that the stock may be overvalued and volatile, with a concrete signal to confirm this being a decline in revenue growth or a failure to expand margins, which would break the bull thesis and lead to a re-rating of the stock, particularly if the debt-to-equity ratio of 0.78 becomes a concern.
Horizon. 1-3 yr $240.25 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $351.75 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $521.80 if current growth sustains into durable earnings power.
24. DECK — Deckers Outdoor Corporation · score 78.6
Footwear & Accessories · price $104.56 · 1Y $126.86 · 5Y $185.73 · 10Y $275.52
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 14.9x A- · PEG 1.32 B
Why now. Deckers Outdoor Corporation is a high-quality compounder driven by the sustained global demand for its HOKA performance footwear and the enduring appeal of its UGG casual lifestyle brand. The company's impressive 18.7% profit margin and $1.1b in TTM free cash flow, alongside a healthy 9.8% FY YoY revenue growth, demonstrate robust operational efficiency and strong cash generation. This combination positions DECK to continue investing in its core brands and distribution, fueling persistent earnings growth.
Moat. DECK's durable edge stems from the powerful brand equity and category leadership of HOKA in performance footwear (running, trail, hiking) and UGG in casual lifestyle. With an exceptional 41% Return on Equity, the company exhibits significant pricing power and efficient capital deployment, driven by its ability to command premium pricing and expand distribution through both domestic and international retailers. This brand strength and diversified portfolio make it challenging for competitors to quickly replicate DECK's market position.
Risk. The primary risk for Deckers Outdoor Corporation lies in its exposure to discretionary consumer spending and potential shifts in fashion trends, particularly for its UGG and Koolaburra casual footwear lines, or increased competition in the high-performance activities segment for HOKA. A Beta of 1.15 indicates higher market volatility, and a PEG ratio of 1.32 suggests growth expectations are already baked into the valuation. A concrete signal confirming the bear case would be a sustained deceleration in revenue growth below the current 9.8% coupled with a significant contraction in profit margins.
Horizon. 1-3 yr $126.86 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $185.73 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $275.52 if current growth sustains into durable earnings power.
25. NFLX — Netflix, Inc. · score 78.4
Entertainment · price $73.81 · 1Y $114.15 · 5Y $167.12 · 10Y $247.91
FCF $11.9b A- · Rev +15.9% B+ · D/E 0.54 B · P/E 23.8x B · PEG 1.41 B
Why now. Netflix remains a high-quality compounder, leveraging its unparalleled global content library of TV series, documentaries, feature films, games, and live programming to drive subscriber and revenue expansion. With a robust 15.9% FY YoY revenue growth and an impressive 28.5% profit margin, the company is generating substantial free cash flow of $11.9b TTM, which it can reinvest or return to shareholders. The crux of the thesis rests on Netflix's persistent ability to scale its content creation and distribution network, ensuring continued global market penetration and pricing power.
Moat. Netflix's durable moat stems from its vast, ever-expanding library of "TV series, documentaries, feature films, games, and live programming" combined with its ubiquitous global distribution network across "internet-connected devices." This scale creates a powerful network effect, allowing for massive content investments that smaller competitors cannot match, reinforcing its category leadership. An exceptional 43% Return on Equity reflects this pricing power and operational efficiency derived from its dominant position in streaming entertainment.
Risk. The primary risk to Netflix lies in the intensifying competition within the global "entertainment services" market, where a proliferation of streaming options could cap subscriber growth and inflate content acquisition costs for "TV series, documentaries, feature films, games, and live programming." While growth is strong, the stock's 23.8 P/E multiple is vulnerable to any deceleration, especially given its high 1.49 beta. A sustained trend of declining revenue growth below 15.9% and a noticeable erosion of the 28.5% profit margin would confirm the bear thesis.
Horizon. 1-3 yr $114.15 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $167.12 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $247.91 if current growth sustains into durable earnings power.
26. HURN — Huron Consulting Group Inc. · score 78.2
Consulting Services · price $98.73 · 1Y $184.25 · 5Y $269.76 · 10Y $400.17
FCF $124m C · Rev +11.7% B · D/E 2.24 D · P/E 16.9x A- · PEG 1.47 B
Why now. Huron Consulting Group is a compelling growth story, leveraging its deep expertise in digital services and operational performance improvement to capture significant market share in the critical Healthcare and Education sectors. With robust revenue growth of 11.7% year-over-year, a healthy free cash flow of $124m, and an impressive 26.1% Return on Equity, HURN demonstrates both expansion and efficient capital deployment. The crux of the thesis rests on the persistent demand for complex digital transformation, particularly in enterprise health record and artificial intelligence/automation, where HURN provides mission-critical solutions.
Moat. HURN's durable edge stems from its specialized knowledge and long-standing client relationships within the highly regulated and complex Healthcare and Education segments. By offering bespoke digital services like enterprise health record and enterprise resource planning implementations, alongside revenue cycle managed services, HURN embeds itself deeply into client operations, creating high switching costs. The company's 26.1% ROE is a direct result of its pricing power derived from this specialized expertise and the mission-critical nature of its solutions, which are difficult for generalist competitors to replicate quickly.
Risk. The primary bear case against HURN centers on its elevated debt-to-equity ratio of 2.24, which could expose the company to financial strain if client spending in its core Healthcare or Education segments slows significantly. While HURN's services are critical, a prolonged economic downturn or increased competition in specific digital service offerings could pressure margins and project backlogs. A sustained contraction in client project pipeline or a noticeable increase in client churn, particularly within its managed services offerings, would confirm the bear case and challenge the bull thesis.
Horizon. 1-3 yr $184.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $269.76 at ~22% CAGR — compounding case rests on the competitive position widening. 10 yr $400.17 if current growth sustains into durable earnings power.
27. DV — DoubleVerify Holdings, Inc. · score 77.8
Advertising Agencies · price $10.82 · 1Y $13.06 · 5Y $19.12 · 10Y $28.36
FCF $135m C · Rev +13.9% B+ · D/E 0.09 A- · P/E 32.8x C+ · PEG 0.62 A-
Why now. DoubleVerify's critical role in digital media quality, exemplified by its DV Authentic Ad and DV Authentic Attention platforms, positions it for continued expansion as advertisers demand verifiable ROI in a complex digital landscape. With a compelling PEG Ratio of 0.62 and a healthy 13.9% FY YoY revenue growth, the market is underappreciating its compounding potential. The company's ability to generate $135m in TTM free cash flow at a 7.2% profit margin underscores its operational efficiency, making it a high-quality compounder in the essential ad verification space. The crux lies in the persistent demand for independent, transparent ad measurement across an ever-fragmenting digital ecosystem.
Moat. The moat for DoubleVerify is built on its deep integration into the digital advertising ecosystem, providing essential, independent third-party verification through platforms like DV Authentic Ad and DV Authentic Attention. Advertisers face significant switching costs once their campaigns and measurement systems are configured with DV's comprehensive suite, which includes Custom Contextual solution and Scibids AI. This embedded position, coupled with specialized data and AI capabilities, creates a sticky relationship with customers who rely on DV's technology to ensure ad effectiveness and brand safety, making it difficult for new entrants to replicate.
Risk. The primary bear case against DoubleVerify centers on the cyclical nature of the broader digital advertising market, which directly impacts demand for its media effectiveness platforms. Despite a reasonable P/S TTM of 2.2, the P/E TTM of 32.8 is still elevated for a company with 13.9% revenue growth, suggesting vulnerability to any slowdown in ad spend. Furthermore, the increasing sophistication of in-house measurement tools from major ad platforms could reduce the perceived necessity of third-party solutions like DV Authentic Ad or DV Authentic Attention. A sustained deceleration in revenue growth below current levels, coupled with contracting profit margins, would confirm the bear thesis.
Horizon. 1-3 yr $13.06 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $19.12 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $28.36 if current growth sustains into durable earnings power.
28. QCOM — QUALCOMM Incorporated · score 77.4
Semiconductors · price $189.39 · 1Y $213.00 · 5Y $311.85 · 10Y $462.61
FCF $12.5b A- · Rev +13.7% B+ · D/E 0.56 B · P/E 20.4x B+ · PEG 0.84 B+
Why now. QUALCOMM presents a compelling growth opportunity, trading at a highly attractive PEG Ratio of 0.84, indicating its growth is undervalued relative to its peers. The company continues to demonstrate robust expansion with 13.7% FY YoY revenue growth, fueled by its foundational wireless technologies extending beyond mobile into high-growth segments like automotive systems for ADAS/AD and IoT edge networking. With a substantial $12.5B in TTM Free Cash Flow, QCOM possesses ample capital to invest in these strategic initiatives and return value to shareholders, making its diversification into these new markets the crux of its compounding thesis.
Moat. QCOM's durable edge stems from its deep intellectual property portfolio, particularly within its Qualcomm Technology Licensing (QTL) segment, which underpins the entire wireless industry. This extensive patent library creates significant barriers to entry and high switching costs for manufacturers integrating its foundational technologies into mobile, automotive, and IoT devices. The exceptional 36.4% Return on Equity is a testament to this formidable moat, reflecting the pricing power and high-margin licensing revenue generated from its category leadership in wireless connectivity and computing technologies.
Risk. The primary bear case against QCOM centers on its elevated market volatility and potential for cyclical headwinds, evidenced by its high Beta of 1.6, which amplifies downside risk during broader market corrections. While growth is strong, the current P/E of 20.4 could be seen as stretched if the company's expansion into automotive and IoT segments fails to offset any slowdown in its core mobile device market. A sustained deceleration in revenue growth below 13.7% or a contraction in its impressive 22.3% profit margin would signal a weakening competitive position and confirm the bear thesis.
Horizon. 1-3 yr $213.00 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $311.85 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $462.61 if current growth sustains into durable earnings power.
29. EAT — Brinker International, Inc. · score 76.4
Restaurants · price $171.46 · 1Y $184.90 · 5Y $270.71 · 10Y $401.58
FCF $504m C+ · Rev +21.9% A- · D/E 4.31 D · P/E 16.7x B+ · PEG 0.89 B+
Why now. Brinker International is a compelling growth compounder, demonstrating exceptional top-line expansion for a restaurant operator with 21.9% FY YoY revenue growth. This robust performance, driven by its Chili's Grill & Bar and Maggiano's Little Italy brands, is available at an attractive valuation, indicated by a low 0.89 PEG ratio. The company's ability to generate substantial free cash flow of $504m TTM further underpins its capacity for reinvestment and shareholder returns, making it a high-quality name compounding value in the casual dining segment.
Moat. The company's durable edge stems from its established and widely recognized casual dining brands, Chili's Grill & Bar and Maggiano's Little Italy, which have built significant brand equity and customer loyalty since 1975. This long-standing presence provides a substantial distribution advantage and operational scale, making it difficult for new entrants to quickly replicate their footprint or capture market share in the competitive restaurant sector. Their deep market penetration and consistent customer experience in casual dining create a sticky customer base.
Risk. The primary bear case against Brinker International centers on its elevated financial leverage, with a high 4.31 debt-to-equity ratio, which could amplify risks during economic downturns or periods of rising interest rates. Furthermore, the company's 1.28 beta indicates higher volatility than the broader market, suggesting its casual dining segment is particularly sensitive to discretionary consumer spending shifts. A sustained contraction in consumer spending, leading to decelerating revenue growth below current levels, would confirm the bear case and strain its highly leveraged balance sheet.
Horizon. 1-3 yr $184.90 (analyst consensus (n=20)) — fundamentals + valuation re-rating. 5 yr $270.71 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $401.58 if current growth sustains into durable earnings power.
30. FISV — Fiserv, Inc. · score 76.1
Sector n/a · price $49.45 · 1Y $70.00 · 5Y $102.49 · 10Y $152.03
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.4x A- · PEG 2.33 C
Why now. Fiserv presents a compelling growth-at-a-reasonable-price opportunity, boasting $4.1B in free cash flow against a $26.4b market cap, translating to a substantial FCF yield. This robust cash generation, combined with a solid 9.3% revenue growth rate and a low 8.4x P/E, positions FISV as a high-quality compounder. The crux is the company's ability to continue deploying this cash flow efficiently to drive per-share value in the consolidating payments sector.
Moat. Fiserv's durable edge in payment processing is built on the high switching costs associated with its deeply integrated, mission-critical technology solutions for financial institutions and merchants. These complex systems become embedded in client operations, creating significant friction for any potential migration to competitors. The company's consistent 19.7% profit margin reflects the sticky nature of its enterprise-grade offerings and its established market position.
Risk. The primary bear case for Fiserv stems from the intense competitive pressures within the payments processing industry, which could constrain future growth and compress its 19.7% profit margin. Despite its growth classification, the stock trades significantly below its 52-week high of $175.92 at just $49.45, reflecting investor concerns about its ability to accelerate growth or maintain pricing power. A sustained decline in its 12.2% ROE or a further deceleration in revenue growth would confirm the bear thesis.
Horizon. 1-3 yr $70.00 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $102.49 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $152.03 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.